News

Merck has suspended patient enrollment in two Phase 3 clinical trials, KEYNOTE-183 and KEYNOTE-185, testing Keytruda (pembrolizumab) in combination with other therapies in patients with multiple myeloma, due to unexplained deaths in study participants taking the company’s anti-PD-1 therapy. Patients already enrolled and under treatment will continue receiving the…

Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study, the largest precision medicine trial to date. Caris will also evaluate next-generation sequencing results for certain trial participants. The NCI-MATCH trial (NCT02465060) was designed to evaluate…

Updated results from an ongoing Phase 1 clinical study of bb2121, an investigational therapy for the treatment of multiple myeloma, show that 100% of patients responded to active doses of the treatment, Bluebird bio and Celgene Corporation announced.

An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA therapy, called LCAR-B38M, induced tumor responses in all 35 enrolled patients, and 94 percent experienced complete or near complete durable remissions. The findings were recently presented…

Oncology Venture has enrolled the first patient into a Phase 1/2 trial of its compound APO010 in multiple myeloma. Patients in the study will be pre-screened using a drug response predictor tool, which indicates they are likely to respond to the treatment. This companion diagnostic, which the company calls…

Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated results from the ongoing Phase 3 POLLUX study (NCT02076009) and Phase 3 CASTOR study (NCT02136134). The findings will be presented June 5 at the the…

The first research program dedicated to the early detection and prevention of multiple myeloma will  be under way soon, thanks to a $4 million Perelman Family Foundation donation to the Multiple Myeloma Research Foundation. The Perelman Family Foundation Early Disease Translational Research Program will be established as part of the myeloma…

Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according to the T-cell treatment’s developer, Adaptimmune Therapeutics. To qualify for the study, patients’ tumor cells must express the NY-ESO or LAGE-1 proteins, or both. Expression is…

A Phase 2 trial has shown that Keytruda (pembrolizumab) increases the effectiveness of Pomalyst (pomalidomide) and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). The study also shows that PD-L1 activity on myeloma cells and PD-1 on bone marrow-infiltrating T-cells are possible biomarkers for the effectiveness of PD-1 (programmed death 1)…

Patients with advanced multiple myeloma who received three or more lines of therapy have shown promising safety and efficacy results in a Phase 1 trial assessing bluebird bio’s new CAR T-cell therapy bb2121. New data, to be presented at…